AstraZeneca PLC Market Performance and News Summary for June 26, 2026
Stock Market Performance
- Current Price: $188.41 (up +1.47% at close)
- Previous Close: $185.68
- Day's Range: $184.28 - $189.57
- Volume: 3,235,235 shares traded (above average volume of 1,978,379)
- Market Capitalization: $292.198 billion
- PE Ratio (TTM): 28.33
- 52-Week Range: $137.22 - $212.71
- Year-to-Date Performance: +1.83%
- 1-Year Return: +35.20%
- 5-Year Return: +58.73%
Notable Recent News
-
New Partnerships: AstraZeneca has entered a five-year partnership with the YMCA to expand cancer care programs across the USA. This initiative focuses on addressing cancer care gaps and includes financial support for program expansion.
Read more -
Regulatory Updates: The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of AstraZeneca's drug Datroway as a first-line treatment for metastatic triple-negative breast cancer patients who are not candidates for immunotherapy.
Read more -
Analyst Insights: Analysts have set an average price target of $224.49 for AstraZeneca (AZN). UBS recently upgraded the rating to "Buy," reflecting a positive outlook on the company's growth potential.
Read analyst details
Earnings Reports and Future Projections
- Next Earnings Date: July 27, 2026
- Estimated Q2 FY26 EPS: $1.27
- Q1 FY26 Revenue: $15.29 billion
- Q1 FY26 Earnings: $4.03 billion
Current Market Context
AstraZeneca's stock exhibited resilience today, closing higher despite broader market indices showing declines. The stock outperformed several peers in the healthcare sector, highlighting its strong market positioning amid volatility.
Company Overview and Summary
AstraZeneca PLC is a global biopharmaceutical company engaged in the discovery, development, manufacture, and commercialization of prescription medicines. The company focuses on therapeutic areas including oncology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines, and rare diseases. Key products include Imjudo, Tagrisso, Lynparza, and Farxiga.
Today’s stock performance paired with recent strategic partnerships and regulatory approvals suggests a positive trajectory for AstraZeneca. Analyst optimism, reflected in price target upgrades and strong recent returns, supports the company’s growth outlook. These developments reinforce AstraZeneca’s competitive position and potential for sustained growth.
Explore more exclusive insights at nextfin.ai.
